Immunogenicity of the CoronaVac vaccine in children: a real-world study
BackgroundDespite its proven effectiveness and safety, there are limited real-world data on CoronaVac’s immunogenicity in children, especially in lower-income countries, particularly for SARS-CoV-2 variants. We present a real-world study evaluating CoronaVac’s immunogenicity in Colombian children st...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1504935/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846111698649350144 |
|---|---|
| author | Wbeimar Aguilar-Jimenez Ana Lucia Rodriguez-Perea Mateo Chvatal-Medina Paula A. Velilla Wildeman Zapata-Builes Wildeman Zapata-Builes Laura M. Monsalve-Escudero Maria I. Zapata-Cardona Jorge Humberto Tabares-Guevara Daniel S. Rincón Juan C. Hernandez Juan C. Hernandez Yulied Tabares Liliana Lopez-Carvajal Maria T. Rugeles |
| author_facet | Wbeimar Aguilar-Jimenez Ana Lucia Rodriguez-Perea Mateo Chvatal-Medina Paula A. Velilla Wildeman Zapata-Builes Wildeman Zapata-Builes Laura M. Monsalve-Escudero Maria I. Zapata-Cardona Jorge Humberto Tabares-Guevara Daniel S. Rincón Juan C. Hernandez Juan C. Hernandez Yulied Tabares Liliana Lopez-Carvajal Maria T. Rugeles |
| author_sort | Wbeimar Aguilar-Jimenez |
| collection | DOAJ |
| description | BackgroundDespite its proven effectiveness and safety, there are limited real-world data on CoronaVac’s immunogenicity in children, especially in lower-income countries, particularly for SARS-CoV-2 variants. We present a real-world study evaluating CoronaVac’s immunogenicity in Colombian children stratified by previous exposure to this virus.Methods89 children aged 3-11 years were enrolled (50 Non-Exposed and 39 Exposed). Saliva samples were collected every 15 days to monitor potential SARS-CoV-2 infection, and blood samples were taken at two and six months after vaccination, to evaluate immunogenicity. Total IgG and IgA antibodies were measured by ELISA, and neutralizing titers against B.1, Delta, Mu, and Omicron variants were assessed by plaque reduction assay. T-cells were stimulated with wild-type and Omicron peptide pools to analyze activation-induced markers, memory phenotype, cytotoxic molecules, and cytokine production by flow cytometry.FindingsCoronaVac was well tolerated, with only 7.8% infection incidence in both Exposed and Non-Exposed groups. It elicits a robust humoral response through IgG, IgA, and neutralizing antibodies against all variants. Despite waning, most participants maintained neutralizing titers ≥20 over time. CoronaVac also induced a polyfunctional cellular response against various strains, albeit reduced against Omicron, regardless of prior exposure. This response, characterized by IFN-γ/TNF-α and cytotoxic molecule production, was more pronounced in CD4+ than in CD8+ T-cells and remained detectable even after 6 months.InterpretationCoronaVac induces robust humoral and cellular immune responses against various variants in children, suggesting cross-recognition. However, these responses diminish over time, particularly in the context of variants, indicating the need for booster doses. |
| format | Article |
| id | doaj-art-83cb6729931d47abbb5bd0f00f0032f2 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-83cb6729931d47abbb5bd0f00f0032f22024-12-23T06:38:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.15049351504935Immunogenicity of the CoronaVac vaccine in children: a real-world studyWbeimar Aguilar-Jimenez0Ana Lucia Rodriguez-Perea1Mateo Chvatal-Medina2Paula A. Velilla3Wildeman Zapata-Builes4Wildeman Zapata-Builes5Laura M. Monsalve-Escudero6Maria I. Zapata-Cardona7Jorge Humberto Tabares-Guevara8Daniel S. Rincón9Juan C. Hernandez10Juan C. Hernandez11Yulied Tabares12Liliana Lopez-Carvajal13Maria T. Rugeles14Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Infettare, Universidad Cooperativa de Colombia, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaGrupo Infettare, Universidad Cooperativa de Colombia, Medellín, ColombiaGrupo de Investigación Clínica PECET (GIC-PECET), Universidad de Antioquia, Medellín, ColombiaGrupo de Investigación Clínica PECET (GIC-PECET), Universidad de Antioquia, Medellín, ColombiaGrupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, ColombiaBackgroundDespite its proven effectiveness and safety, there are limited real-world data on CoronaVac’s immunogenicity in children, especially in lower-income countries, particularly for SARS-CoV-2 variants. We present a real-world study evaluating CoronaVac’s immunogenicity in Colombian children stratified by previous exposure to this virus.Methods89 children aged 3-11 years were enrolled (50 Non-Exposed and 39 Exposed). Saliva samples were collected every 15 days to monitor potential SARS-CoV-2 infection, and blood samples were taken at two and six months after vaccination, to evaluate immunogenicity. Total IgG and IgA antibodies were measured by ELISA, and neutralizing titers against B.1, Delta, Mu, and Omicron variants were assessed by plaque reduction assay. T-cells were stimulated with wild-type and Omicron peptide pools to analyze activation-induced markers, memory phenotype, cytotoxic molecules, and cytokine production by flow cytometry.FindingsCoronaVac was well tolerated, with only 7.8% infection incidence in both Exposed and Non-Exposed groups. It elicits a robust humoral response through IgG, IgA, and neutralizing antibodies against all variants. Despite waning, most participants maintained neutralizing titers ≥20 over time. CoronaVac also induced a polyfunctional cellular response against various strains, albeit reduced against Omicron, regardless of prior exposure. This response, characterized by IFN-γ/TNF-α and cytotoxic molecule production, was more pronounced in CD4+ than in CD8+ T-cells and remained detectable even after 6 months.InterpretationCoronaVac induces robust humoral and cellular immune responses against various variants in children, suggesting cross-recognition. However, these responses diminish over time, particularly in the context of variants, indicating the need for booster doses.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1504935/fullreal-world studyCOVID-19 vaccinechildrenimmunogenicityneutralizing antibodiesomicron variant |
| spellingShingle | Wbeimar Aguilar-Jimenez Ana Lucia Rodriguez-Perea Mateo Chvatal-Medina Paula A. Velilla Wildeman Zapata-Builes Wildeman Zapata-Builes Laura M. Monsalve-Escudero Maria I. Zapata-Cardona Jorge Humberto Tabares-Guevara Daniel S. Rincón Juan C. Hernandez Juan C. Hernandez Yulied Tabares Liliana Lopez-Carvajal Maria T. Rugeles Immunogenicity of the CoronaVac vaccine in children: a real-world study Frontiers in Immunology real-world study COVID-19 vaccine children immunogenicity neutralizing antibodies omicron variant |
| title | Immunogenicity of the CoronaVac vaccine in children: a real-world study |
| title_full | Immunogenicity of the CoronaVac vaccine in children: a real-world study |
| title_fullStr | Immunogenicity of the CoronaVac vaccine in children: a real-world study |
| title_full_unstemmed | Immunogenicity of the CoronaVac vaccine in children: a real-world study |
| title_short | Immunogenicity of the CoronaVac vaccine in children: a real-world study |
| title_sort | immunogenicity of the coronavac vaccine in children a real world study |
| topic | real-world study COVID-19 vaccine children immunogenicity neutralizing antibodies omicron variant |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1504935/full |
| work_keys_str_mv | AT wbeimaraguilarjimenez immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT analuciarodriguezperea immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT mateochvatalmedina immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT paulaavelilla immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT wildemanzapatabuiles immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT wildemanzapatabuiles immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT laurammonsalveescudero immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT mariaizapatacardona immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT jorgehumbertotabaresguevara immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT danielsrincon immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT juanchernandez immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT juanchernandez immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT yuliedtabares immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT lilianalopezcarvajal immunogenicityofthecoronavacvaccineinchildrenarealworldstudy AT mariatrugeles immunogenicityofthecoronavacvaccineinchildrenarealworldstudy |